Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Market watchers are anticipating strong growth driven by the strong demand of Lilly's blockbuster medications, particularly its insulin portfolio. However, there are also concerns about potential